Tech Company Financing Transactions
Nucleai Funding Round
Debiopharm Diagnostics, Grove Ventures and Vertex Ventures participated in a $6.5 million Series A capital raise for Nucleai. The financing closed on 7/7/2020.
Transaction Overview
Company Name
Announced On
7/7/2020
Transaction Type
Venture Equity
Amount
$6,500,000
Round
Series A
Investors
Proceeds Purpose
We plan to use these funds to expand our offering to additional indications and diseases as well as to increase our commercial footprint substantially.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1375 W Fulton Ave. 650
Chicago, IL 60607
USA
Chicago, IL 60607
USA
Phone
Undisclosed
Website
Email Address
Overview
We are transforming precision medicine with AI-powered pathology. Our team's work is a unique collaboration of experienced AI technologists, physicians and exceptional healthcare research professionals.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Avi Veidman
Chief Medical Officer
Ori Zelichov
Chief Operating Officer
Eliron Amir
Chief Technical Officer
Albert Achtenberg
VP - R & D
Lotan Chorev
VP - Sales
Jonathan Daniels
Browse more venture capital transactions:
Prev: 7/7/2020: Caffeine venture capital transaction
Next: 7/7/2020: Flinks venture capital transaction
Share this article
Where The Data Comes From
We do our best to document funding rounds that are announced publicly. VC transactions reported here come from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs